You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Enabling new possibilities in endoscopy
We began by focusing on lung cancer and have since helped hospitals treat more than 20,000 patients.1 Next, we are helping physicians tackle kidney stones. Additional indications bring the potential to treat more patients in the least invasive way possible.
Lung cancer claims as many lives each year as breast, colon, and prostate cancers combined2
of nodules are located in the peripheral third of the lung3
Americans will experience kidney stones4
Up to 50%
Patients will need a repeat kidney stone procedure.5
Inconclusive diagnosis of lung nodules means patients must wait and watch or possibly undergo multiple biopsy procedures to stage and diagnose. MONARCH™ helps physicians confront challenges to aid in earlier diagnosis.
Kidney stones affect patients everywhere. The MONARCH™ Platform aims to support urologists in their mission to help patients become stone-free in a single minimally invasive procedure
Gateway Customer Portal
Our customers have access to data and insights through our secure web-portal to support their MONARCH™ experience. Improve efficiency with access to platform usage data, order information, training, and marketing support materials.
Transforming medical intervention
With MONARCH™, you have the power of flexible robotics to address unmet clinical needs and improve patient outcomes. Through advanced robotics and micro instrumentation, we are committed to delivering innovative endoscopic possibilities.
Extend to meet patient needs
Because MONARCH™ utilizes extensible architecture it can be used in more procedures, which elevates patient care. The cart is lightweight, allowing for easier transport between rooms, and adding new features by specialty is simple by design.
Collaborating for better outcomes
We, like you, understand the importance of a multi-disciplinary approach to help improve patient outcomes. So, specialists across all of Johnson & Johnson are working together to change the trajectory of lung cancer.
Facts and Publications
Early Detection Saves Lives.
The American Lung Association’s State of Lung Cancer report shows the toll lung cancer takes.
Recent articles and papers.
Bronchoscopy Indications for Use: The MONARCH™ Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures.
Bronchoscopy Important Safety Statement: Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Indications for Use: The MonarchTM Platform, Urology, the ureteroscope, and endourology accessories are indicated to provide endoscopic visualization and access of organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) with transurethral access or transurethral access in conjunction with percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
Urology Important Safety Information:
Adverse effects from ureteroscopy may include pain, perforation of the ureter, urinoma, stricture of the ureter, avulsion of the ureter, urinary tract infection, urosepsis, bleeding, hydronephrosis, blood clots, residual stones, or injury of the ureter.
Minor adverse effects following Mini-PCNL may include fever and nephrostomy leak. Major adverse effects related to access may include injuries to pleura, liver, spleen, colon, duodenum, and jejunum, and may result in bleeding, fever, pain, ileus, elevated counts, and gas or feces from the percutaneous nephrostomy (PCN) tube. Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, post percutaneous nephrolithotomy bleeding, arrhythmia, burns, inflammation, hypothermia, obstruction to the kidney, and injury to soft tissue.
Adverse effects of these procedures may require prolonged surgical duration, additional surgical intervention, or conversion to other surgical techniques.
1. Procedural volume count recorded in SalesForce.com as of 10/06/22
2. "Cancer Stat Facts: Common Cancer Sites." National Cancer Institute, Accessed Sept 12, 2022. https://seer.cancer.gov/statfacts/html/lungb.html
3. Chaddha, U., Kovacs, S.P., Manley, C.et al.Robot-assisted bronchoscopy for pulmonary lesion diagnosis: results from the initial multicenter experience.BMC Pulm Med19,243 (2019) https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-019-1010-8
4. Scales Jr, C.D., Smith, A.C., Hanley, J.M., Saigal, C.S., Urologic Diseases in America Project. (2012). Prevalence of kidney stones in the United States. European urology, 62(1), 160-165
5. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. Nat Rev Dis Primers. 2016;2:16008. Published 2016 Feb 25. doi.org/10.1038/nrdp.2016.8.
MBRPRO-000846-02 Rev B © 2022 Ethicon, Inc. All rights reserved.